# Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

> **NCT05265988** · PHASE2 · COMPLETED · sponsor: **Alfredo Berruti** · enrollment: 32 (actual)

## Conditions studied

- Carcinoma Prostate

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT05265988
- **Lead sponsor:** Alfredo Berruti
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2024-06-29
- **Final completion:** 2024-06-29
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265988, "Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05265988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*